TB-500 with BPC-157: why a combined product is not covered
The one-active-ingredient rule, what it means for anyone offered a “stack,” and how little research there is on the pair.
HHS’s October 2026 policy covers compounded products with one active ingredient each. A product combining TB-500 and BPC-157, often marketed as a “stack,” does not meet that condition, so the policy does not cover it. Human data on the pair amount to four patients in one small chart review. REMEVi does not offer TB-500, BPC-157 or any combination.
TB-500 is not FDA-approved. Since HHS’s October 2026 interim policy, a state-licensed 503A pharmacy may compound it on a patient-specific prescription under listed conditions.
REMEVi does not currently offer TB-500.
Why a combined TB-500 + BPC-157 product is not covered
Both peptides appear in the appendix of HHS’s 2026 policy, but each is listed on its own, with its own routes: TB-500 for subcutaneous or intramuscular injection, BPC-157 for subcutaneous, intramuscular, oral or topical use. The policy’s conditions include one active ingredient per compounded product.
A vial, syringe or kit with both peptides mixed together has two active ingredients. It falls outside the policy, whoever sells it and however it is labelled.
Federal Register notice (Oct 30, 2026) · The 2026 policy, explained
What this means if someone offers you a “stack”
This page explains the rules; it does not recommend combining peptides. If you are offered a TB-500 + BPC-157 product, these facts apply:
- A premixed product is not covered by the 2026 policy, even from a pharmacy.
- A research-use product is outside the policy entirely, single or combined.
- Under the policy, each covered product is a separate prescription for one peptide, from a state-licensed 503A pharmacy, with its own label and its own sourcing documentation.
- Whether any peptide is appropriate for you, alone or alongside another medicine, is a decision for a licensed provider who knows your history. Never self-dose.
Questions worth asking: Is this one active ingredient? Is it compounded by a state-licensed 503A pharmacy on a prescription in my name? Is the label the one the policy requires? Who reports serious adverse events?
What research exists on TB-500 with BPC-157
Very little. The human data on the pair come from a 2021 retrospective chart review of knee injections in which four patients received BPC-157 combined with thymosin beta-4; outcomes were collected by phone, with no control group. No controlled study of the combination has been published.
Each peptide alone has little human evidence: BPC-157 research is mostly in rats, and FDA has identified no human exposure data for TB-500.
Why there is no published combined dose
There is no established human dose for TB-500 or for BPC-157, so there is no basis for a combined dose. Charts that list one are not drawn from human trials. This page does not give blend dosing, and the 2026 policy would not cover the product anyway.
Can you take TB-500 and BPC-157 together?
No controlled human study has tested them together, and HHS’s 2026 policy does not cover a product that combines them, because each compounded product may contain one active ingredient. Whether any peptide is appropriate for you is a decision for a licensed provider who knows your history. Never self-dose.
Is a BPC-157 and TB-500 blend legal?
A premixed BPC-157 and TB-500 product is not covered by HHS’s October 2026 enforcement-discretion policy, which requires one active ingredient per compounded product. Research-use blends sold online are outside the policy altogether. Neither peptide is FDA-approved, and the policy itself is interim and revocable.
Sources
- HHS — Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, notice of availability, 91 FR 68526 (October 30, 2026) (read November 2, 2026)
- Foley & Lardner (Holtz, Beaver, Rosen), National Law Review, Oct 30 2026 — Peptides: HHS announces limited enforcement discretion for compounding six peptides (read November 2, 2026)
- Nutritional Outlook (Bigica), Nov 2 2026 — HHS peptide compounding policy: supplement industry implications (read November 2, 2026)
- Lee & Padgett, Altern Ther Health Med 2021 — Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain (read November 2, 2026)
- FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026) (read November 2, 2026)
- Holland & Knight, Oct 16 2026 — Peptides at a crossroads: what wellness providers need to know (read November 2, 2026)
- AJMC (Steinzor), Oct 29 2026 — 5 things to know about HHS’s interim peptide compounding policy (read November 2, 2026)
Medically reviewed by Linda West-Conforti, RN · CA RN #389453 ·